A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells

Cancer Letters

Volumn 312, Issue 2, 2011, Pages 158-167

  Samadi, Abbas K ^a   Zhang, Xuan ^a   Mukerji, Ridhwi ^a   Donnelly, Alison C ^b   Blagg, Brian S ^b   Cohen, Mark S ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

C terminal; Hsp90 inhibitor; Melanoma

Indexed keywords

B RAF KINASE; CASPASE 3; CYCLIN B; CYTOCHROME C; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; KU 135; LIPOCORTIN 5; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE; RAF PROTEIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL FRACTIONATION; CELL PROLIFERATION; CELL SELECTION; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MELANOMA; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MELANOMA; MEMBRANE POTENTIALS; MITOCHONDRIA; NOVOBIOCIN;

EID: 80053997701     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.031     Document Type: Article

References (33)

1. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
2. Ibrahim N., Haluska F.G. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu. Rev. Pathol. 2009, 4:551-579.
3. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen ST., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
4. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
5. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
6. McCarthy M.M., Pick E., Kluger Y., Gould-Rothberg B., Lazova R., Camp R.L., Rimm D.L., Kluger H.M. HSP90 as a marker of progression in melanoma. Ann. Oncol. 2008, 19:590-594.
7. Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 2005, 56:126-137.
8. Faingold D., Marshall J.C., Antecka E., Di Cesare S., Odashiro A.N., Bakalian S., Fernandes B.F., Burnier M.N. Immune expression and inhibition of heat shock protein 90 in uveal melanoma. Clin. Cancer Res. 2008, 14:847-855.
9. Solit D.B., Osman I., Polsky D., Panageas K.S., Daud A., Goydos J.S., Teitcher J., Wolchok J.D., Germino F.J., Krown S.E., Coit D., Rosen N., Chapman P.B. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 2008, 14:8302-8307.
10. Pacey S., Gore M., Chao D., Banerji U., Larkin J., Sarker S., Owen K., Asad Y., Raynaud F., Walton M., Judson I., Workman P., Eisen T. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest. New Drugs 2010, (August 5).
11. Banerji U., Affolter A., Judson I., Marais R., Workman P. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol. Cancer Ther. 2008, 7:737-739.
12. Kimura H., Yukitake H., Tajima Y., Suzuki H., Chikatsu T., Morimoto S., Funabashi Y., Omae H., Ito T., Yoneda Y., Takizawa M. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation. Chem. Biol. 2010, 17:18-27.
13. Zhang T., Li Y., Yu Y., Zou P., Jiang Y., Sun D. Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J. Biol. Chem. 2009, 284:35381-35389.
14. Shelton S.N., Shawgo M.E., Matthews S.B., Lu Y., Donnelly A.C., Szabla K., Tanol M., Vielhauer G.A., Rajewski R.A., Matts R.L., Blagg B.S., Robertson J.D. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol. Pharmacol. 2009, 76:1314-1322.
15. Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J. Clin. Endocrinol. Metab. 2008, 93:4331-4341.
16. Guettouche T., Boellmann F., Lane W.S., Voellmy R. Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem. 2005, 6:4.
17. Lebret T., Watson R.W., Molinie V., O'Neill A., Gabriel C., Fitzpatrick J.M., Botto H. Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 2003, 98:970-977.
18. Sauvageot C.M., Weatherbee J.L., Kesari S., Winters S.E., Barnes J., Dellagatta J., Ramakrishna N.R., Stiles CD., Kung A.L., Kieran M.W., Wen P.Y. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro-Oncology 2009, 11:109-121.
19. Beloueche-Babari M., Arunan V., Jackson L.E., Perusinghe N., Sharp S.Y., Workman P., Leach M.O. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget 2010, 1:185-197.
20. Mehta P.P., Kung P.P., Yamazaki S., Walls M., Shen A., Nguyen L., Gehring M.R., Los G., Smeal T., Yin M.J. A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells. Cancer Lett. 2011, 300:30-39.
21. Burger A.M., Fiebig H.H., Stinson S.F., Sausville E.A. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004, 15:377-387.
22. Guo F., Rocha K., Bali P., Pranpat M., Fiskus W., Boyapalle S., Kumaraswamy S., Balasis M., Greedy B., Armitage E.S., Lawrence N., Bhalla K. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res. 2005, 65:10536-10544.
23. Taiyab A., Sreedhar A.S., Rao Ch M. Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. Biochem. Pharmacol. 2009, 78:142-152.
24. Davenport E.L., Moore H.E., Dunlop A.S., Sharp S.Y., Workman P., Morgan G.J., Davies F.E. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007, 110:2641-2649.
25. Eletto D., Dersh D., Argon Y. GRP94 in ER quality control and stress responses. Semin. Cell Dev. Biol. 2010, 21:479-485.
26. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K., Pushparajan A., Hayden J.E., Brown K.D., Laquerre S., McArthur G.A., Sosman J.A., Nathanson K.L., Herlyn M. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:83-695.
27. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., Chodon T., Nelson S.F., McArthur G., Sosman J.A., Ribas A., Lo R.S. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:73-977.
28. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson LA., Emery CM., Stransky N., Cogdill A.P., Barretina J., Caponigro G., Hieronymus H., Murray R.R., Salehi-Ashtiani K., Hill D.E., Vidal M., Zhao J.J., Yang X., Alkan O., Kim S., Harris J.L., Wlson C.J., Myer V.E., Finan P.M., Root D.E., Roberts T.M., Golub T., Flaherty K.T., Dummer R., L Weber B., Sellers W.R., Schlegel R., Wargo J.A., Hahn W.C., Garraway LA. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
29. Galaktionov K., Lee A.K., Eckstein J., Draetta G., Meckler J., Loda M., Beach D. CDC25 phosphatases as potential human oncogenes. Science 1995, 269:1575-1577.
30. Forester C.M., Maddox J., Louis J.V., Goris J., Virshup D.M. Control of mitotic exit by PP2A regulation of Cdc25C and Cdkl. Proc. Natl. Acad. Sci. USA 2007, 104:19867-19872.
31. Timofeev O., Cizmecioglu O., Settele F., Kempf T., Hoffmann I. Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J. Biol. Chem. 2010, 285:16978-16990.
32. Basto R., Gergely F., Draviam V.M., Ohkura H., Liley K., Raff J.W. Hsp90 is required to localise cyclin B and Msps/ch-TOG to the mitotic spindle in Drosophila and humans. J. Cell Sci. 2007, 120:1278-1287.
33. Senju M., Sueoka N., Sato A., Iwanaga K., Sakao Y., Tomimitsu S., Tominaga M., Irie K., Hayashi S., Sueoka E. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J. Cancer Res. Clin. Oncol. 2006, 132:150-158.